OncoSil Medical Limited (ASX:OSL) has appointed ex-Cochlear CEO Dr Chris Roberts AO as Non-Executive Chairman of its Board.
Mr Roberts was originally appointed to the company's Board in January last year. He was appointed an Officer in the Order of Australia in 2017 for his service to science and the development and commercialisation of medical biotechnology.
He served as CEO and President of Cochlear for over a decade, from 2004 to 2015, and has previously served as Chairman of Sirtex Medical and executive vice-president of global sleep disorder treatment company ResMed. He is currently a non-executive director of ResMed.
OncoSil is focused on the development and commercialisation of treatments for pancreatic and liver cancer.
Dr Roberts holds a BE (Honours) in Chemical Engineering (UNSW), an MBA (Macquarie University) and a PhD (UNSW) and was awarded Honorary Doctor of Sciences degrees from Macquarie University and the University of NSW.
OncoSil Medical CEO Daniel Kenny said: “We are grateful for the contribution of Dr Roberts since he joined OncoSil as a Non-Executive Director, and are confident his expertise will continue to prove invaluable as he leads our Board. Dr Roberts boasts a history of success in the development and commercialisation of medical technologies and his new appointment is very timely as we continue to advance toward commercialisation of a medical radiation treatment for pancreatic cancer and other solid tumors.”
In response to his appointment, Dr Roberts said: “I am excited to lead the Board as OncoSil draws nearer to commercialising its innovative technology which has the potential to significantly improve the lives of people with cancer. There have been several rewarding developments in recent months with the progression of the global pancreatic study programme, and I look forward to extending my involvement in the company’s overall direction.”